Construction and enhanced cytotoxicity of a [cyanovirin-N]-[Pseudomonas exotoxin] conjugate against human immunodeficiency virus-infected cells.

Cyanovirin-N (CV-N) is a novel 11-kDa anti-HIV(human immunodeficiency virus) protein that binds with high affinity to the viral envelope glycoprotein gp120. In contrast to soluble CD4 and most known neutralizing antibodies that bind gp120, CV-N exerts potent anti-viral activity against primary clinical HIV isolates as well as laboratory-adapted strains of HIV. Here we describe the recombinant production, purification, and characterization of a chimeric toxin molecule, FLAG-CV-N-PE38, that contains CV-N as a gp120-targeting moiety linked to the translocation and cytotoxic domains of Pseudomonas exotoxin A. FLAG-CV-N-PE38 showed enhanced cytotoxicity to HIV-infected, gp120-expressing H9 cells compared to uninfected H9 cells. Competition experiments with free CV-N provided further support that the enhanced FLAG-CV-N-PE38-induced cytotoxicity was due to interactions of the CV-N moiety with cell surface gp120. This study establishes the feasibility of use of CV-N as a gp120-targeting sequence for construction and experimental therapeutic investigations of unique new chimeric toxins designed to selectively destroy HIV-infected host cells.

[1]  L K Pannell,et al.  Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development , 1997, Antimicrobial agents and chemotherapy.

[2]  P. Bates.  Chemokine Receptors and HIV-1: An Attractive Pair? , 1996, Cell.

[3]  G. Allaway,et al.  Increase in sensitivity to soluble CD4 by primary HIV type 1 isolates after passage through C8166 cells: association with sequence differences in the first constant (C1) region of glycoprotein 120. , 1995, AIDS research and human retroviruses.

[4]  J. Metcalf,et al.  Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus. , 1994, The Journal of infectious diseases.

[5]  D. Katzenstein,et al.  Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons. , 1994, The Journal of infectious diseases.

[6]  I. Pastan,et al.  Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma , 1994 .

[7]  P. Murphy.  The molecular biology of leukocyte chemoattractant receptors. , 1994, Annual review of immunology.

[8]  J. Moore,et al.  Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates , 1992, Journal of virology.

[9]  I. Pastan,et al.  Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor alpha at different locations in Pseudomonas exotoxin. , 1992, Bioconjugate chemistry.

[10]  M. Boyd,et al.  A semiautomated multiparameter approach for anti-HIV drug screening. , 1991, Journal of virological methods.

[11]  D. Capon,et al.  The CD4-gp120 interaction and AIDS pathogenesis. , 1991, Annual review of immunology.

[12]  F. Wurm,et al.  Biological properties of a CD4 immunoadhesin , 1990, Nature.

[13]  R. Schooley,et al.  Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. , 1990, Annals of internal medicine.

[14]  K. Karjalainen,et al.  Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules , 1989, Nature.

[15]  V. Ghetie,et al.  HIV-infected cells are killed by rCD4-ricin A chain. , 1988, Science.

[16]  I. Pastan,et al.  Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein , 1988, Nature.

[17]  W. Lüke,et al.  Soluble CD4 molecules neutralize human immunodeficiency virus type 1 , 1988, Nature.

[18]  R. Axel,et al.  soluble form of CD4 (T4) protein inhibits AIDS virus infection , 1988, Nature.

[19]  B. Walker,et al.  HIV infection is blocked in vitro by recombinant soluble CD4 , 1988, Nature.

[20]  I. Pastan,et al.  Functional domains of pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli , 1987, Cell.

[21]  Robin A. Weiss,et al.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain , 1986, Cell.

[22]  K. Steimer,et al.  Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein , 1986, Nature.

[23]  J. Sodroski,et al.  Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity , 1986, Nature.

[24]  R. Gallo,et al.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. , 1984, Science.

[25]  M. Inouye,et al.  Amino acid sequence of the signal peptide of ompA protein, a major outer membrane protein of Escherichia coli. , 1980, The Journal of biological chemistry.